Results 1 to 10 of about 13,325 (156)
Comparative efficacy and safety of topical caspofungin 0.5% and voriconazole 1% for fungal keratitis: a pilot clinical trial [PDF]
Scientific ReportsTo compare the efficacy of topical caspofungin 0.5% with topical voriconazole 1% in patients with fungal keratitis. In this pilot clinical trial, thirty-four eyes from 34 patients diagnosed with fungal keratitis, confirmed by positive smear or culture ...
Mehrnaz Atighehchian +6 more
doaj +2 more sources
Caspofungin binding to iron compromises its antifungal efficacy against Candida albicans [PDF]
Communications BiologyEchinocandins, which inhibit the synthesis of β-1,3-D-glucans, essential components of the fungal cell wall, are frontline drugs for invasive fungal infections (IFIs) caused by Candida spp.
Andreia Pedras +12 more
doaj +2 more sources
International Journal of Infectious Diseases, 2022 Objectives: Increased resistance of Candida species, especially Candida. glabrata is problematic. Combination antifungal therapies were studied to solve the problem.
Qianting Yang +6 more
doaj +1 more source
Saudi Pharmaceutical Journal, 2022 Objective: The aim of this study is to evaluate the utilization pattern of Caspofungin in an academic tertiary care hospital in Riyadh, Saudi Arabia. Methods: This is a retrospective study, conducted at King Saud University Medical City, Riyadh, Saudi ...
Abrar F. Alshehri +3 more
doaj +1 more source
Microbiology Spectrum, 2022 Candida species are the main fungal opportunistic pathogens causing systemic infections that are often associated with drug resistance and biofilm production on medical devices.
Roberta Fais +4 more
doaj +1 more source
Caspofungin MIC Distribution amongst Commonly Isolated Candida Species in a Tertiary Care Centre - An Indian Experience [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Emergence of Candida species resistant to Amphotericin B and triazole has led to use of echinocandins, mostly caspofungin in the management of invasive candidiasis.
Shashir Wanjare +2 more
doaj +1 more source
Clinical Infectious Diseases, 2003 Caspofungin, the first inhibitor of fungal beta-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. It is also active in vitro and in animal models against a number of other filamentous and dimorphic endemic fungi and ...
Louis D. Saravolatz +2 more
openaire +2 more sources
mSphere, 2022 The fungal pathogen Cryptococcus neoformans causes up to 278 000 infections each year globally, resulting in up to 180,000 deaths annually, mostly impacting immunocompromised people. Therapeutic options for C.
Brenda Moreira-Walsh +6 more
doaj +1 more source
Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. [PDF]
PLoS ONE, 2013 Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for ...
Maria Luísa Lobo +6 more
doaj +1 more source
Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China
Journal of Global Antimicrobial Resistance, 2021 : Objectives: Effective antifungal therapy is important to reduce mortality in patients with invasive fungal infections (IFIs). Numerous factors affect pharmacokinetic/pharmacodynamic (PK/PD) parameters in critically-ill patients.
Fangyi Li +5 more
doaj +1 more source